跳至主要内容
临床试验/NCT03348917
NCT03348917已完成4 期

The Effect of Skin Cleansers on the Skin Surface Microbiome

Mundipharma Manufacturing Pte Ltd.1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2017年12月28日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
15
试验地点
1
主要终点
Composition of skin microbiome - reduction of microflora amount

研究概览

简要总结

This study determines the effects of a single application of different antiseptic skin cleansers on the composition of the skin surface microbiome using next-generation sequencing (NGS) techniques. Twelve healthy volunteers will receive all three test products in a randomized order to compare the effects of each skin cleanser.

详细描述

Disinfectants and oral antiseptics including PVP-I are known to kill microorganisms to a variable extent, at a variable range of time points. Microorganisms may be protected from disinfectants by production of thick masses of cells and extracellular materials, or biofilms. Moreover, antiseptics should not lead to dysbiosis after use. Dysbiosis is a negative change in the microbiome of a particular skin or mucosal region. The Human Microbiome project showed, that every area has a specific microbiota in which the human host lives with an abundance of commensal, synergistic, and potentially pathogenic microorganisms. Antiseptics with efficacy gaps and resistance may induce such dysbiosis, especially after prolonged use. It is envisaged that twelve healthy volunteers will complete the study. Each healthy volunteer will apply the test product according to a developed protocol, between established wash out periods.

The ability of the test product (Commercially available - Betadine® 7.5% skin cleanser (PVP-I 7.5%)) compared to the reference products (commercially available 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol) and Plain non antibacterial soap - Guardian gel hand wash (not medicated)) to reduce resident and transient microflora will be assessed. The hand wash products will also be assessed for their ability to maintain and/or restore balanced microflora.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Sequential
主要目的
Prevention
盲法
Single (Outcomes Assessor)

盲法说明

Single

入排标准

年龄范围
21 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male and female subjects between age 21 to 65 years
  • Must wear short sleeved shirts/blouses during each visit
  • Non-smoker
  • Good general and mental health with, in the opinion of investigator or the qualified medical designee:
  • No clinically significant and relevant abnormalities of medical history or physical examination;
  • Absence of any condition that would impact the subject's safety or health or affect the subject's ability to understand and comply with the study procedures.
  • Prepared to use the provided wash products that do not contain any antimicrobials (non antibacterial shampoo [Pantene® Pro-V], non antibacterial body wash [Dove®body wash] and non antibacterial hand wash [Guardian gel hand wash]) after providing consent and during the whole study
  • Healthy and intact skin in the test area (e.g., no skin allergy, visible bleeding, skin inflammation, skin ulcer or skin lesion, no need for cutaneous treatment)
  • Must have given written informed consent
  • Women of child-bearing potential who are, in the opinion of the investigator, practicing a reliable method of contraception.

排除标准

  • Women who are pregnant or have a positive urine pregnancy test or intending to become pregnant during the overall study period
  • Women who are breast-feeding
  • Allergy or contraindication to any test product substance (active or excipients)
  • Any visible signs of skin dermatitis on the hands, e.g., eczema
  • Use of anti-dandruff shampoo or any other shampoo/hand/body wash products apart from those provided, within 2 days prior to Visit 2 (Day 0) and also during the whole study
  • Systemic or topical or oral antibiotic or antifungal in the past 2 months before Screening and during the study
  • Medication use (e.g., lithium therapy, immunosuppressive medication, systemic or inhaled glucocorticoids) in the past 2 months before Screening and during the study
  • Recent history (within the last 1 year) of alcohol or other substance abuse
  • Known hyperthyroidism or other ongoing thyroid diseases
  • Minor ailments such as like cough, cold, upper respiratory tract infection(s) within 2 weeks and during the study
  • Any known serious ongoing disease
  • Unwillingness or inability to comply with the requirements of the protocol
  • Participation in any other drug, biologic, device, or clinical study or treatment with any investigational drug or approved therapy for investigational use within 30 days (or 5 half-lives, whichever is longer) before Screening
  • An employee of the sponsor or study site or their immediate family member
  • Subject who has been treated with cancer within the last 1 year.

研究组 & 干预措施

Treatment sequence Group 1

Active Comparator

Treatment Sequence Group 1 = A -> B -> C

Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)

Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)

Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)

干预措施: 7.5% Povidone-Iodine [PVP-I] (Drug)

Treatment sequence Group 1

Active Comparator

Treatment Sequence Group 1 = A -> B -> C

Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)

Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)

Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)

干预措施: 4% chlorhexidine skin cleanser (Drug)

Treatment sequence Group 1

Active Comparator

Treatment Sequence Group 1 = A -> B -> C

Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)

Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)

Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)

干预措施: Plain non antibacterial soap (Drug)

Treatment sequence Group 2

Active Comparator

Treatment Sequence Group 2 = B -> C -> A

Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)

Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)

Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)

干预措施: 7.5% Povidone-Iodine [PVP-I] (Drug)

Treatment sequence Group 2

Active Comparator

Treatment Sequence Group 2 = B -> C -> A

Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)

Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)

Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)

干预措施: 4% chlorhexidine skin cleanser (Drug)

Treatment sequence Group 2

Active Comparator

Treatment Sequence Group 2 = B -> C -> A

Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)

Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)

Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)

干预措施: Plain non antibacterial soap (Drug)

Treatment sequence Group 3

Active Comparator

Treatment Sequence Group 3 = C -> A ->B

Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)

Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)

Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)

干预措施: 7.5% Povidone-Iodine [PVP-I] (Drug)

Treatment sequence Group 3

Active Comparator

Treatment Sequence Group 3 = C -> A ->B

Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)

Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)

Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)

干预措施: 4% chlorhexidine skin cleanser (Drug)

Treatment sequence Group 3

Active Comparator

Treatment Sequence Group 3 = C -> A ->B

Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)

Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)

Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)

干预措施: Plain non antibacterial soap (Drug)

结局指标

主要结局

Composition of skin microbiome - reduction of microflora amount

时间窗: [Time Frame: Skin Strip 1: 0 Min, Skin Strip 2: 3 min (post treatment) and Skin Strip 3: 240 min (post treatment)]

The change in amount of skin microflora species composition from baseline after the usage of a single application of different skin cleansers using next generation sequencing (NGS) and real-time PCR techniques at 3 mins and 240 mins.

Composition of skin microbiome - maintenance of healthy microflora amount

时间窗: [Time Frame: Skin Strip 1: 0 Min, Skin Strip 2: 3 min (post treatment) and Skin Strip 3: 240 min (post treatment)]

The change in amount of healthy skin microflora species composition from baseline after the usage of a single application of different skin cleansers using next generation sequencing (NGS) and real-time PCR techniques at 3 mins and 240 mins.

Composition of skin microbiome - reduction of microflora variety

时间窗: [Time Frame: Skin Strip 1: 0 Min, Skin Strip 2: 3 min (post treatment) and Skin Strip 3: 240 min (post treatment)]

The change in variety of skin microflora species composition from baseline after the usage of a single application of different skin cleansers using next generation sequencing (NGS) and real-time PCR techniques at 3 mins and 240 mins.

Composition of skin microbiome - maintenance of healthy microflora variety

时间窗: [Time Frame: Skin Strip 1: 0 Min, Skin Strip 2: 3 min (post treatment) and Skin Strip 3: 240 min (post treatment)]

The change in variety of healthy skin microflora species composition from baseline after the usage of a single application of different skin cleansers using next generation sequencing (NGS) and real-time PCR techniques at 3 mins and 240 mins.

次要结局

未报告次要终点

研究者

发起方
Mundipharma Manufacturing Pte Ltd.
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验